Dose-finding study of AJG533 in patients with chronic constipation (Phase 2 study)
Phase 2
- Conditions
- Chronic constipation
- Registration Number
- JPRN-jRCT2080222557
- Lead Sponsor
- AJINOMOTO PHARMACEUTICALS CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with chronic constipation
Exclusion Criteria
Patient with known or suspected organic constipation
Patient with known or suspected symptomatic constipation or drug-induced constipation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of Spontaneous Bowel Movement
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie AJG533's efficacy in chronic constipation as studied in JPRN-jRCT2080222557?
How does AJG533 compare to standard-of-care laxatives like linaclotide in Phase 2 trials for chronic constipation?
Are there specific biomarkers associated with AJG533 response in patients with slow-transit constipation?
What adverse events were reported in Ajinomoto Pharmaceuticals' Phase 2 AJG533 trial for chronic constipation?
What are the therapeutic advantages of AJG533 over other guanylate cyclase-C agonists in constipation management?